Actinobac Biomed

Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Actinobac’s drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera® are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis. For the millions of patients who suffer from blood cancers, autoimmune diseases, and inflammatory conditions, Actinobac offers new hope because their products specifically target and eliminate the diseased cells. This means greater benefit with fewer side effects. Actinobac’s goal is to not just change lives, but also save them. Year Founded: 2009 Key Executive: • Dr. Scott Kachlany, Founder and Chief Scientific Officer Location: Kendall Park, NJ Website: http://www.actinobac.com/ Company Status: Private Year Invested: 2017 Investment Status: Current Board Member: Alex Andrianopoulos The approval clears the way for Kachlany’s company, Actinobac Biomed, to initiate a phase I clinical... We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made... Copyright © 2024 Kairos Venture Investments, LLC.